Geovax Labs is a biotechnology company that focuses on developing innovative vaccines and immunotherapies for infectious diseases and cancer. With a particular emphasis on addressing public health concerns, Geovax leverages its proprietary technology platform to create novel medical solutions aimed at enhancing immune responses. The company is involved in various stages of research and development, working to advance its projects through clinical trials and collaborations with other research entities, committed to improving health outcomes and combating significant health threats. Read More
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps.
Continued Mpox Evolution Underscores Dependence on a Single Global Supplier, Reinforcing the Critical Importance of GeoVax’s Accelerated GEO-MVA Program
ATLANTA, GA - December 19, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company's common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance.
Animal Models Show Full Protection Against Omicron Variant Despite Absence of Neutralizing Antibodies, Highlighting Critical Importance of T-cell Immunity for Next-generation COVID-19 Vaccines
Patent Strengthens GeoVax’s Multi-Antigen Vaccine Platform Designed to Deliver Broader, Longer-Lasting Protection and Support Future Pandemic Preparedness
ATLANTA, GA - November 24, 2025 ( NEWMEDIAWIRE ) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at NobleCon21 - the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference taking place December 2-3, 2025 in Boca Raton, FL.
